Ellen G. Driever

Ellen G. Driever

Auto-generated profile, based on publicly available information

Ellen G. Driever

Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Hepatology
Verified
Journal Article
Open access
PDF file
EDEllen G. Driever
Ellen G. Driever
FMFien A. von Meijenfeldt
Fien A. von Meijenfeldt
JAJelle Adelmeijer
Jelle Adelmeijer
RHRobbert J. de Haas
Robbert J. de Haas
MHMarius C. van Den Heuvel
Marius C. van Den Heuvel
TLTon Lisman
Ton Lisman
Background and Aim: Portal vein thrombosis (PVT) is a common complication of cirrhosis. The exact pathophysiology remains largely unknown, and treatment with anticoagulants does not lead to recanalization of the portal vein in all patients. A better insight into the structure and composition of portal vein thrombi may assist in developing strategies for the prevention and treatment of PVT. Approach and Results: Sixteen prospectively and 63 retrospectively collected nonmalignant portal vein thrombi from patients with cirrhosis who underwent liver transplantation were included. Histology, immunohistochemistry, and scanning electron microscopy were used to assess structure and composition of the thrombi. Most recent CT scans were reanalyzed for thrombus characteristics. Clinical characteristics were related to histological and radiological findings. All samples showed a thickened, fibrotic tunica intima. Fibrin‐rich thrombi were present on top of the fibrotic intima in 9/16 prospective cases and in 21/63 retrospective cases. A minority of the fibrotic areas stained focally positive for fibrin/fibrinogen (16% of cases), von Willebrand factor (VWF; 10%), and CD61 (platelets, 21%), while most of the fibrin‐rich areas stained positive for those markers (fibrin/fibrinogen, 100%; VWF, 77%; CD61, 100%). No associations were found between clinical characteristics including estimated thrombus age and use of anticoagulants and presence of fibrin‐rich thrombi. Conclusion: We demonstrate that PVT in patients with cirrhosis consists of intimal fibrosis with an additional fibrin‐rich thrombus in only one‐third of cases. We hypothesize that our observations may explain why not all portal vein thrombi in patients with cirrhosis recanalize by anticoagulant therapy.

11 July 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
EDEllen G. Driever
Ellen G. Driever
MMMarta Magaz
Marta Magaz
JAJelle Adelmeijer
Jelle Adelmeijer
FTFanny Turon
Fanny Turon
ABAnna Baiges
Anna Baiges
TLTon Lisman
Ton Lisman
A hypercoagulable state is not associated with development of portal vein thrombosis in cirrhosis, as we previously demonstrated. However, some groups demonstrated elevated levels of inflammatory markers and activation of hemostasis in the portal vein (PV) compared to posthepatic veins, but because the liver is involved in clearance of these markers, we hypothesize that interpretation of these data is not straightforward. To determine whether the PV has particular proinflammatory/hypercoagulable characteristics by comparing plasma sampled in the PV, hepatic vein (HV), and the systemic circulation. Plasma samples from 51 cirrhotic patients with portal hypertension undergoing transjugular intrahepatic portosystemic shunt placement, were taken from the PV, HV, and jugular vein (JV). Markers of inflammation (lipopolysaccharide, tumor necrosis factor‐α, interleukin‐6, thiobarbituric acid‐reactive substances), neutrophil‐extracellular‐traps (cfDNA, MPO‐DNA), endothelial damage (von Willebrand factor [VWF]), and hemostasis were determined and compared among the three vascular beds. Markers of inflammation were slightly, but significantly higher in the PV than in the HV and systemic circulation. VWF and markers of hemostasis were modestly elevated in the PV. Levels of multiple markers were lower in the HV compared with the PV and systemic circulation. Higher model for end‐stage liver disease score was associated with a more prothrombotic state in all three sample sites. In contrast to published studies, we did not detect a clear proinflammatory or prothrombotic environment in the PV of cirrhotic patients. Many markers are lowest in the HV, indicating that the low levels of these markers in the HV, at least in part, reflect clearance of those markers in the liver.

8 February 2022 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Open access
PDF file
EDEllen G. Driever
Ellen G. Driever
TLTon Lisman
Ton Lisman
Patients with liver diseases are in a rebalanced state of hemostasis, due to simultaneous decline in pro- and anticoagulant factors. This balance seems to remain even in the sickest patients, but is less stable and might destabilize when patients develop disease complications. Patients with acute decompensation of cirrhosis, acute-on-chronic liver failure, or acute liver failure often develop complications associated with changes in the hemostatic system, such as systemic inflammation. Systemic inflammation causes hemostatic alterations by adhesion and aggregation of platelets, release of von Willebrand factor (VWF), enhanced expression of tissue factor, inhibition of natural anticoagulant pathways, and inhibition of fibrinolysis. Laboratory tests of hemostasis in acutely-ill liver patients may indicate a hypocoagulable state (decreased platelet count, prolongations in prothrombin time and activated partial thromboplastin time, decreased fibrinogen levels) due to decreased synthetic liver capacity or consumption, or a hypercoagulable state (increased VWF levels, hypofibrinolysis in global tests). Whether these changes are clinically relevant and should be corrected with antithrombotic drugs or blood products is incompletely understood. Inflammation and activation of coagulation may cause local ischemia, progression of liver disease, and multiorgan failure. Anti-inflammatory treatment in acutely-ill liver patients may be of potential interest to prevent thrombotic or bleeding complications and halt progression of liver disease.

4 February 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
EDEllen G. Driever
Ellen G. Driever
SCSuzanne C. Cannegieter
Suzanne C. Cannegieter
SGStephen Gregory
Stephen Gregory
PKPauline Kane
Pauline Kane
YZYoh Zen
Yoh Zen
WBWilliam Bernal
William Bernal
The exact pathophysiology of portal vein thrombosis (PVT), a common complication of cirrhosis, remains largely unknown. We previously found that cirrhotic PVT consists of fibrotic intimal thickening of the portal vein wall rather than of true fibrin-rich thrombus. We hypothesized that this portal vein intimal thickening is secondary to portal hypertension and/or to local inflammatory responses. The intimal thickness of right and left portal branches was measured in hilar liver samples from 232 cirrhotic patients without PVT who underwent liver transplantation. The relation between intimal thickness and pre-transplant clinical variables was studied with linear regression. CT-scans of 25 patients prior to liver transplantation were reanalysed for portal vein and portal hypertension-related characteristics. Median right intimal thickness was 129 (1 - 300 (IQR)) μm, median left intimal thickness was 112 (1 - 230) μm and there was correlation between intimal thickness in the right and left branches in individual patients (r = 0.30, P<.001). Intimal thickness of the portal vein was associated with a history of variceal bleeding, hepatic encephalopathy or ascites, etiology of disease and statin use. Other factors, including duration of liver disease, presence of infection, or radiological characteristics were not significantly associated with intimal thickness. Intrahepatic portal vein intimal thickness is highly variable in patients with cirrhosis, but relatively consistent between right and left portal branches. The association between intimal thickness and history of variceal bleeding suggests that portal hypertension may contribute to initiation of intimal thickening, and consequently to the development of PVT.

28 October 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
EDEllen G. Driever
Ellen G. Driever
WBWilliam Bernal
William Bernal
TLTon Lisman
Ton Lisman

9 January 2023 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
EDEllen G. Driever
Ellen G. Driever
ABAnnabel Blasi
Annabel Blasi
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
TLTon Lisman
Ton Lisman